More Frequent Home Haemodialysis Therapy

Clinically Differentiated Treatment Option for Home Patients.

The NxStage System One is designed as a simple and practical option for patients to perform haemodialysis therapy in the comfort of their own home.

Many healthcare professionals recognise the limitations of traditional in-centre therapy, and accept that more frequent home haemodialysis, performed more than 3 days per week, may improve quality of life, patient outcomes, and survival.1-3 More than 90 percent of nephrologists said they would choose a home dialysis therapy for themselves if informed they needed renal replacement therapy, with home haemodialysis being the preferred option.4

The NxStage System One is the only truly portable home haemodialysis system that offers individualised treatment options that fit within your patient’s lifestyle; during the day or overnight as your patient and care partner sleep.

More frequent haemodialysis eliminates the two-day gap in treatments and can offer patients access to life-changing clinical benefits. Whether patients are new to dialysis or need to transition from their existing therapy, NxStage can help. Providing patient education on the types of therapies available can help you and your patients select the modality that fits their life and lifestyle.

By working together to explain all the modalities available to your patients, including more frequent home haemodialysis, we can improve lifestyles and clinical outcomes for the growing number of dialysis patients today.

Risks and Responsibilities

Despite the health benefits that home and more frequent hemodialysis may provide to those with chronic kidney disease, these forms of therapy are not for everyone. Home hemodialysis with the NxStage System One requires a patient and partner who are committed to being trained on and following the guidelines for proper system operation.

The reported benefits of home hemodialysis may not be experienced by all patients.

The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. When vascular access is exposed to more frequent use, infection of the site, and other access related complications may also be potential risks. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set.

Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep.

Patients should consult their doctor to understand the risks and responsibilities of performing these therapies using the NxStage System.

  1. Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily hemodialysis improves the long-term health-related quality of life. Kidney Int. 2012;82(5):561-569.
  2. FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300.
  3. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol. 2012;23(5):895-904.
  4. Merighi JR, Schatell DR, Bragg-Gresham JL, Witten B, Mehrotra R. Insights into nephrologist training, clinical practice, and dialysis choice. Hemodial Int. 2012;16(2):242-251.
APM2080-ENG Rev. A

Fresenius Medical Care has successfully completed its merger with NxStage Medical, Inc.

More Info